---
title: "Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations"
description: "Formulary evidence on Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations. 1 evidence topic quoted from 0 sources."
canonical: "https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/terms-and-abbreviations"
published: "2026-11-15T20:23:59-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Terms and abbreviations

<a id="terms-and-abbreviations"></a>

## Terms and Abbreviations

<a id="topic-terms-and-abbreviations-1"></a>

| Abbreviation | Term |
| --- | --- |
| AAO | American Academy of Ophthalmology |
| ABS | Australian Bureau of Statistics |
| ACP | Avacincaptad pegol |
| ADA | Anti-drug antibody |
| AE | Adverse event |
| AESI | Adverse event of special interest |
| AHFS | American Hospital Formulary Service |
| AMD | Age-related macular degeneration |
| AMP | Average manufacturer price |
| AREDS | Age-Related Eye Disease Study |
| AREDS2 | Age-Related Eye Disease Study 2 |
| ARMS2 | Age-related maculopathy susceptibility 2 |
| ATC | Anatomical Therapeutic Chemical classification |
| BCVA | Best-corrected visual acuity |
| BL | Baseline |
| BLA | Biologics license application |
| BQL | Below the quantification limit |
| BrM | Bruch's membrane |
| BSC | Best supportive care |
| CAM | Classification of Atrophy Meetings |
| CBS | Charles Bonnet syndrome |
| CFB | Complement factor B |
| CFH | Complement factor H |
| CFI | Complement factor I |
| CFP | Color fundus photography |
| CHO | Chinese hamster ovary |
| CI | Confidence interval |
| CMS | Centers for Medicare & Medicaid Services |
| CNV | Choroidal neovascularization |
| CPT | Current Procedural Terminology |
| cRORA | Complete retinal pigment epithelium and outer retinal atrophy |
| CrI | Credible interval |
| CUA | Cost-utility analysis |
| DHA | Docosahexaenoic acid |
| DMC | Data Monitoring Committee |
| DME | Diabetic macular edema |
| DSMC | Data and Safety Monitoring Committee |
| DUSC | Drug Utilisation Sub-Committee |
| ECP | Eye care professional |
| ED | Emergency department |
| EM | Every month |
| EMA | European Medicines Agency |
| EOM | Every other month |
| EPA | Eicosapentaenoic acid |
| EQ-5D | EuroQol 5-dimension questionnaire |
| ER | Emergency room |
| ESC | Economics Sub-Committee |
| ETDRS | Early Treatment Diabetic Retinopathy Study |
| EU | European Union |
| EZ | Ellipsoid zone |
| Fab | Antigen-binding fragment |
| FAF | Fundus autofluorescence |
| FDA | U.S. Food and Drug Administration |
| FRI | Functional Reading Independence |
| GA | Geographic atrophy |
| GBS | Guillain-Barré syndrome |
| GP | General practitioner |
| GWAS | Genome-wide association study |
| HCPCS | Healthcare Common Procedure Coding System |
| HCRU | Healthcare resource utilization |
| HR | Hazard ratio |
| HTRA1 | High-temperature requirement A serine peptidase 1 |
| ICER | Incremental cost-effectiveness ratio |
| INN | International nonproprietary name |
| IOP | Intraocular pressure |
| IQR | Interquartile range |
| iRORA | Incomplete retinal pigment epithelium and outer retinal atrophy |
| IRIS | Intelligent Research in Sight registry |
| ITT | Intention-to-treat |
| IVT | Intravitreal |
| LL | Letter loss |
| LLD | Low-luminance deficit |
| LLVA | Low-luminance visual acuity |
| LLVD | Low-luminance visual acuity deficit |
| LME | Linear mixed effect |
| logMAR | Logarithm of the minimum angle of resolution |
| MAA | Marketing authorisation application |
| MBS | Medicare Benefits Schedule |
| MHRA | Medicines and Healthcare products Regulatory Agency |
| MIPS | Merit-based Incentive Payment System |
| mITT | Modified intention-to-treat |
| MMRM | Mixed model for repeated measures |
| MNV | Macular neovascularization |
| nAMD | Neovascular age-related macular degeneration |
| NEI VFQ-25 | National Eye Institute Visual Function Questionnaire, 25-item version |
| NH | Nursing home |
| NICE | National Institute for Health and Care Excellence |
| NIR | Near-infrared reflectance |
| OCT | Optical coherence tomography |
| OCT-A | Optical coherence tomography angiography |
| OLE | Open-label extension |
| OP | Outpatient |
| OPL | Outer plexiform layer |
| OR | Odds ratio |
| PBAC | Pharmaceutical Benefits Advisory Committee |
| PBM | Photobiomodulation |
| PBS | Pharmaceutical Benefits Scheme |
| PD | Pharmacodynamics |
| PDC | Product Development Coordinator |
| PEG | Polyethylene glycol |
| PK | Pharmacokinetics |
| POS | Photoreceptor outer segments |
| PPP | Preferred Practice Pattern |
| PPY | Per patient per year |
| PRIME | PRIority MEdicines |
| QALY | Quality-adjusted life-year |
| QoL | Quality of life |
| RCT | Randomized controlled trial |
| REMS | Risk Evaluation and Mitigation Strategy |
| ReST | Research and Safety in Therapeutics |
| RPBS | Repatriation Pharmaceutical Benefits Scheme |
| RPE | Retinal pigment epithelium |
| RR | Relative risk |
| RVU | Relative value unit |
| SAE | Serious adverse event |
| SCODI | Scanning computerized ophthalmic diagnostic imaging |
| SD | Standard deviation |
| SD-OCT | Spectral-domain optical coherence tomography |
| SE | Standard error |
| SFI | Subfoveal involvement |
| SS-OCT | Swept-source optical coherence tomography |
| TEAE | Treatment-emergent adverse event |
| TTD | Time to treatment discontinuation |
| UI | Uncertainty interval |
| VA | Visual acuity |
| VEGF | Vascular endothelial growth factor |
| VI | Visual impairment |
| VL | Vision loss |
| VRQoL | Vision-related quality of life |
| WHO | World Health Organization |
| WT | Wild type |
| ZBI | Zarit Burden Interview |

## Related pages
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration.md)
- [Vonaprument (ANX007): Geographic atrophy secondary to age-related macular degeneration](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/executive-summary.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Product information and disease description](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/product-information-and-disease-description.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Clinical evidence](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/clinical-evidence.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: Economic information and modeling report](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/economics.md)
- [Vonaprument (ANX007) in Geographic atrophy secondary to age-related macular degeneration: References](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references) · [Markdown](https://www.evicenter.com/drugs/vonaprument--geographic-atrophy-secondary-to-age-related-macular-degeneration/references.md)
